安奈儿(002875.SZ)公告称，公司控股股东、实际控制人曹璋、王建青与深圳新创源投资合伙企业（有 限合伙）签署了《股份转让协议》，拟通过转让公司股份的方式，使新创源获得公司控制权。公司股票 将于2025年6月10日开市起 复牌。本次交易事项尚需经尽职调查、交易所合规性审核及办理股份协议转 让过户相关手续，存在重大不确定性。 ...

证券代码：000403 证券简称：派林生物 公告编号：2025-030 派斯双林生物制药股份有限公司 关于控股股东签署《收购框架协议》暨公司控制权拟发生变更的 提示性公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏。 特别提示： 股股东共青城胜帮英豪投资合伙企业（有限合伙） （以下简称"胜帮英豪"）签署了《收 购框架协议》，胜帮英豪拟将所持派斯双林生物制药股份有限公司（以下简称"公司"） 公司实际控制人将由陕西省人民政府国有资产监督管理委员会变更为中国医药集团有 限公司。中国生物及胜帮英豪将按照《上市公司收购管理办法》等有关法律、法规、部 门规章及规范性文件规定履行相关义务。 成不利影响，不存在损害公司及中小股东利益的情形，亦不存在违反相关承诺的情形。 议》开展尽职调查工作，尽职调查完成后，各方将确定是否签署协议，本次交易存在后 续协议签署时间待定、未能签署及交易无法达成的风险。另外，本次交易尚需取得深圳 证券交易所的合规性确认意见并在中国证券登记结算有限责任公司深圳分公司办理股 份过户登记手续以及完成相关法律法规要求可能涉及的其他批准，该事项能否最终实施 ...

傅启明，1958 年出生，拥有中国香港籍，毕业于台湾交通大学电信工程学系，获得学士学位。自 1983 年起，他便投身集成电路设计业，开启了在该领域的精彩征程。 他的早期职业生涯，先后在联华电子股份有限公司集成电路设计部门担任设计工程师，以及在飞利浦集 成电路设计部门担任资深工程师。在联华电子工作期间，傅启明积累了扎实的技术基础，深入参与到集 成电路设计的实际工作中，对行业的技术发展趋势有了初步但深刻的洞察。随后在飞利浦，凭借其深厚 的技术功底，他进一步接触到国际先进的设计理念和技术标准，这为他后续的职业发展提供了更为广阔 的视野。 6 月 8 日，中颖电子发布公告称，公司控股股东威朗国际集团有限公司正在筹划公司控制权变更相关事 宜，公司股票自 6 月 9 日开市起停牌，预计停牌时间不超过 2 个交易日。 公告显示，目前交易各方尚未签署相关协议，拟就具体交易方案、协议等相关事项进行论证和磋商，具 体情况以各方签订的相关协议为准，该事项可能导致公司控股股东及实际控制人发生变更。 中颖电子 2024 年年报显示，威朗国际是公司控股股东，实控人为傅启明，截至 2025 年第一季度末，威 朗国际直接持有中颖电子 18. ...

Group 1 - The company, Tibet Yiming Xiya Pharmaceutical Technology Co., Ltd., experienced abnormal stock trading fluctuations on June 5 and June 6, 2025, as per the relevant regulations [1] - The board of directors confirmed that there are no undisclosed significant matters affecting the company's stock price, apart from the disclosed share transfer agreement with Beijing Fuhai, which involves the acquisition of 43,855,883 shares from the controlling shareholder Gao Fan [1][2] - The company has disclosed the necessary documents regarding the change of control, including a brief and detailed report on equity changes, and has confirmed that there are no other undisclosed matters that could impact the stock price [2] Group 2 - The company will continue to comply with legal and regulatory requirements for information disclosure and will ensure timely updates regarding any significant changes [2] - The completion of the equity change is subject to compliance confirmation from the Shenzhen Stock Exchange and other necessary approvals, indicating potential uncertainties in the implementation of the transaction [2]

Core Viewpoint - Honghui Fruits and Vegetables (stock code: 603336) is planning a share transfer that may lead to a change in control of the company, as notified by its controlling shareholder Huang Junhui [1][3]. Group 1: Company Overview - Honghui Fruits and Vegetables was established in 1992 and is headquartered in Shantou, Guangdong Province. It was listed on the Shanghai Stock Exchange on November 24, 2016, and is recognized as a key leading enterprise in agricultural industrialization [3][4]. - The company operates under several well-known brands, including "Honghui Fruits and Vegetables," "Honghui Food," and "Monkey Community," with a presence in various regions including Guangdong, Shanghai, and overseas in Malaysia [4]. Group 2: Business Operations - Honghui Fruits and Vegetables specializes in the management of fruit and vegetable products, including post-harvest acquisition, cold chain storage, processing, and distribution. It also engages in the production and distribution of frozen foods and edible oils [4]. Group 3: Financial Performance - In the 2024 annual report, the company reported a revenue of 1.08 billion yuan, a decrease of 0.52% year-on-year, and a net profit attributable to shareholders of 18.30 million yuan, down 23.59% year-on-year [4]. - The 2025 Q1 report indicated a revenue of 246 million yuan, an increase of 13.71% year-on-year, but a net profit of approximately 4.50 million yuan, a decline of 44.38% year-on-year, primarily due to falling sales prices in the fruit business [4]. Group 4: Market Performance - As of June 6, the stock price of Honghui Fruits and Vegetables was 6.24 yuan per share, with a total market capitalization of 3.56 billion yuan. The stock has seen a cumulative increase of 46.14% since the beginning of the year [5].

Core Viewpoint - The leading bathroom company, Diao Home, is at a critical juncture, potentially facing a change in control as its major shareholders plan to alter their unified action [1][3]. Group 1: Company Background and Control Change - Diao Home's major shareholders, Liu Jin, Chen Wei, and Wu Zhixiong, are considering a change in control, which may involve the actual controller of Chengdu Shuihua Zhiyun Technology Co., Ltd., Zhu Jiang [1][4]. - The company was founded in the 1990s by Liu Jin, Chen Wei, and Wu Zhixiong, who initially made their fortune in agate before transitioning to the acrylic sanitary ware market [7][8]. - Diao Home, previously known as Diwang Sanitary Ware, went public in 2016 and later acquired the ceramic giant Oushennuo, rebranding itself as Diao Home [1][8]. Group 2: Financial Performance - Diao Home's market value has plummeted by over 10 billion, with revenue dropping from 6.147 billion in 2021 to 2.741 billion in 2024, marking a significant decline [1][11]. - The company's net profit has been in a continuous loss for three years, with losses of 1.509 billion, 658 million, and 569 million recorded from 2022 to 2024 [11][12]. - The revenue from both distribution and engineering channels has decreased, with the engineering channel seeing a staggering 51.93% drop in 2024 [11]. Group 3: Management and Employee Trends - Despite the declining performance, the total compensation for the management team has increased, contrasting with a reduction in employee numbers from 6,848 in 2021 to 3,942 in 2024 [2][14]. - The management's total pre-tax compensation rose from 4.4278 million in 2021 to 6.6734 million in 2024, while the number of employees decreased significantly [14]. Group 4: Future Outlook - Diao Home's stock price has fallen over 80% from its peak of 43.7 yuan per share, with a current market value of only 2.243 billion [14]. - The potential change in control raises questions about whether the company can revitalize under new leadership [14].

作为卫浴行业的头部家居企业，帝欧家居迎来了新控股股东。 6月5日晚间，帝欧家居（002798.SZ）发布公告称，公司实控人刘进、陈伟、吴志雄与朱江于6月5日签 署了《一致行动协议》，公司实控人变更为朱江、刘进、陈伟、吴志雄。 刘进、陈伟、吴志雄、朱江以及朱江的一致行动人合计持有帝欧家居权益比例为26.46%。与此同时， 四位实控人在上市公司可转债转股、一致行动、推动上市公司可转债的有效化解、流动性支持等方面达 成战略合作。 据每日经济新闻，1983年出生的朱江，在金融机构历练多年后，开始进军资本市场。他曾涉足三泰控股 （川发龙蟒前身）、三五互联（琏升科技前身）和迅游科技。 在公司控制权可能发生变更的背后，是帝欧家居近年来业绩和资产状况上的承压。 帝欧家居是国内最早一批卫浴生产制造企业，后通过并购方式延伸至陶瓷产业，公司在成都、重庆、佛 山、广西、景德镇地区拥有六个建筑陶瓷、卫生洁具生产基地。 在朱江正式"入主"之前，上市公司股价"抢跑"。帝欧家居停牌前两日，6月2日、3日，公司股价、债券 价格双双先行大涨，累计涨幅分别为14.72%、8.51%。从三月朱江等开始增持帝欧家居以来，公司股价 累计涨幅已经超过47 ...

Core Viewpoint - The control of Diou Home (SZ002798) has changed hands to Zhu Jiang, Liu Jin, Chen Wei, and Wu Zhixiong as of June 5, 2023, following the signing of a concerted action agreement. Zhu Jiang is the actual controller of Chengdu Shuihua Hulian Technology Co., which holds 100% of Chengdu Shuihua Zhiyun Technology Co., a significant shareholder of Diou Home [1][2][4]. Group 1: Control Change and Shareholding - On June 5, 2023, Diou Home announced a change in its actual controller to Zhu Jiang and others, indicating a shift in company governance [1][4]. - As of the announcement date, Zhu Jiang and his concerted actors hold a combined 26.46% equity in Diou Home, establishing them as the actual controllers [4][6]. - Prior to this, on May 17, 2023, Shuihua Zhiyun had increased its stake in Diou Home, acquiring approximately 12.87 million shares and 526,200 convertible bonds, bringing their total equity to 5.000011% [2][4]. Group 2: Financial Performance and Challenges - Diou Home has faced declining performance and asset conditions, with a reported accumulated deficit of 1.258 billion yuan as of December 31, 2024, exceeding one-third of its paid-in capital of 394 million yuan [6]. - The company operates in the bathroom and building ceramics sector, with brands including "Diwang" sanitary ware and "Oushinou" ceramics [5][6]. Group 3: Zhu Jiang's Background - Zhu Jiang, born in 1983, is an experienced player in the capital market, having previously been involved with companies such as San Tai Holdings and San Wu Hulian [1][7]. - He has held significant positions in various financial institutions and has been a key figure in several companies, showcasing his extensive experience in corporate governance and investment [8][9].

Group 1 - The controlling shareholder of the company is planning a change in control, leading to a suspension of the company's stock starting June 6, 2025 [2][4][6] - The stock suspension is expected to last no more than two trading days to ensure fair information disclosure and protect investor interests [6] - The company has recently faced regulatory penalties due to internal control issues, with warnings issued to two former chairmen and related management personnel [8][10] Group 2 - An investigation revealed that the company's subsidiary signed supplementary agreements with certain clients and promoters that were not included in the internal control management system, resulting in inaccurate information disclosure [10] - The company is primarily engaged in the research, development, production, and sales of blood products, which are critical national strategic reserve materials and emergency medications for major diseases [10] - The company aims to enhance its profitability by increasing product quantity through R&D innovation and plans to expand its blood product business while actively exploring a second growth avenue for sustainable development [10] Group 3 - As of June 5, the company's stock price was 16.96 yuan per share, with a total market capitalization of 16.1 billion yuan [11]

Group 1 - The core point of the announcement is the signing of a supplementary agreement regarding the delegation of voting rights, indicating a potential change in control of the company [1][2] - The controlling shareholder, Sun Jianxi, intends to transfer 34,936,110 shares, representing 11% of the total shares, to Shanghai Mangrui Enterprise Management Partnership [1][2] - Following the transfer, the total shares held by Sun Jianxi and Li Taijie will be 57,812,390 shares, which accounts for 18.20% of the total shares [2][4] Group 2 - The supplementary agreement modifies certain terms of the original voting rights delegation agreement, confirming the delegation of voting rights for 57,812,390 shares [3][4] - The previous number of delegated shares was 41,932,340, which represented 13.20% of the total shares, indicating an increase in the delegated voting rights [4] - The implementation of this equity change is subject to compliance review by the Shenzhen Stock Exchange and the China Securities Depository and Clearing Corporation [4]